Home > Insider Trading > Filing (0001562180-21-005947)

Filing Details

Accession Number:: 0001562180-21-005947
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-09-15 16:15:54
Reporting Period:: 2021-09-13

Accepted Time:: 2021-09-15 16:15:54
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1590877	Regenxbio Inc.	RGNX	Biological Products, (No Disgnostic Substances) (2836)	471851754

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1652824	T. Kenneth Mills	C/O Regenxbio Inc. 9804 Medical Center Drive Rockville MD 20850	President And Ceo	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-09-13	3,000	$3.76	283,984	No	4	M	Direct
Common Stock	Disposition	2021-09-13	3,000	$40.02	280,984	No	4	S	Direct
Common Stock	Acquisiton	2021-09-14	33,146	$3.76	314,130	No	4	M	Direct
Common Stock	Acquisiton	2021-09-14	1,854	$0.85	315,984	No	4	M	Direct
Common Stock	Disposition	2021-09-14	35,000	$45.11	280,984	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2021-09-13	3,000	$0.00	3,000	$3.76
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2021-09-14	33,146	$0.00	33,146	$3.76
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2021-09-14	1,854	$0.00	1,854	$0.85

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
266,000	2025-05-18	No	4	M	Direct
232,854	2025-05-18	No	4	M	Direct
37,816	2024-09-23	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $45.00 to $45.55. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.
The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter.